Targeting species-specific trace amine-associated receptor 1 ligands: to date perspective of the rational drug design process

Future Med Chem. 2017 Sep;9(13):1507-1527. doi: 10.4155/fmc-2017-0044. Epub 2017 Aug 9.

Abstract

G-protein-coupled receptors represent main targets of several clinically relevant drugs, playing nowadays a leading part for further drug discovery process. Trace amine-associated receptor's family (TAARs) assumed an intriguing role as druggable target in medicinal chemistry, being TAAR1 the most investigated. Indeed, related ligands proved to be intertwined in several circuits involved in pathological pathways or therapeutic routes. Herein, we highlight relevant efforts in the search of novel agonists, focusing on responsiveness featured by different chemotypes toward rodent and human TAAR1, in order to explore species-specificity preferences. We also discuss the main strategies guiding so far the design of new TAAR1 agonists, giving a perspective of the structure-based methodologies aimed at deriving new insights for more potent and selective derivatives.

Keywords: T1AM; TAAR1; agonists; docking; drug design; homology modeling; thyronamine.

Publication types

  • Review

MeSH terms

  • Animals
  • Binding Sites
  • Drug Design*
  • Humans
  • Ligands*
  • Molecular Docking Simulation
  • Receptors, G-Protein-Coupled / agonists
  • Receptors, G-Protein-Coupled / metabolism*
  • Structure-Activity Relationship
  • Thyronines / chemistry
  • Thyronines / metabolism

Substances

  • Ligands
  • Receptors, G-Protein-Coupled
  • Thyronines
  • thyronamine
  • Trace amine-associated receptor 1